Our Chair and Trustees
NCRI is governed by a Board of Trustees. Their role is to set NCRI’s strategy (in consultation with NCRI Partners and other key stakeholders) and uphold our values and governance.
Baroness Delyth MorganBaroness Morgan is the Chief Executive of Breast Cancer Now and sits as a cross bench peer in the House of Lords. She spent 10 years at Breakthrough Breast Cancer, as the charity’s first Chief Executive, before which she worked at Shelter, Workplace Nurseries Campaign and Asthma UK. Delyth is a science graduate and Fellow of University College London. After becoming a life peer she was appointed to Government in 2007, when she served as Children’s Minister for the Department of Children Schools and Families, Minister for Intellectual Property and Quality at the Department of Innovation, Universities and Skills and Government spokesperson for the Department of Work and Pensions in the House of Lords.
Ms Mary BasterfieldMary Basterfield is Chief Financial Officer at Hotels.com, one of the world’s leading accommodation booking websites (and part of NASDAQ listed Expedia Inc) – where she holds global responsibility for the financial management of the business. A qualified accountant (ACMA), Mary’s experience spans e-commerce, strategy, marketing and advertising, and financial management of businesses undergoing rapid change. Previous roles include CFO, Expedia Affiliate Network (Expedia Inc’s private label business-to-business arm) where she also led Strategy and Analytics, and CFO Europe and Vice President Strategy & Acquisitions for Warner Music International. Mary is also a Non-Executive Director and Chair of the Audit Committee for Hounslow and Richmond Community Healthcare NHS Trust, and a Trustee of University College London Union.
Dr Helen CampbellHelen Campbell is Portfolio Manager for Department of Health Research Networks, Cancer Research, and Clinical Research Facilities. She is based at Exeter University Medical School and works full-time on behalf of the Department of Health. After obtaining a PhD in biochemistry, Helen worked in the medical device and pharmaceutical industry, before taking up post in 1994 as manager of the first NHS National Cancer R&D Programme. Since then, Helen has been involved in every major national development in cancer research in the NHS, including the establishment of the National Cancer Research Network and the National Cancer Research Institute.
Mr Alan ChantAlan Chant is a lay member on a number of cancer and research bodies, including Cancer Research UK, the MRC-hosted UK Clinical Research Collaboration Board, NIHR Programme Grants for Applied Research, UK Clinical Trials Gateway Project Board, Wellcome Trust Clinical Study Data Request panel and Oxford Biomedical Research Centre Patients Active in Research Group. He has also served on NICE cancer Guideline Development Groups. He is a Trustee of Oxford Radcliffe Hospitals Charitable Funds. He is also a myeloma cancer patient and has participated in a clinical trial. His business career was spent principally in marketing and business development roles in national and international consumer goods companies and he was a main Board Director in five companies. Academically his qualifications include a BA (Hons) in Business Studies, a post-graduate Diploma in Marketing and an MBA from Henley.
Ms Cathy GilmanCathy Gilman is Chief Executive of Bloodwise. Cathy joined Bloodwise (formerly known as Leukaemia & Lymphoma Research) as a volunteer, becoming corporate fundraiser, Director of Fundraising and CEO in 2007. Her passion is to ensure that the patient is authentically at the heart of Bloodwise, and has focused on understanding the needs of patients. In her time as CEO, in collaboration with the NHS, academia, industry, and some talented individuals, the charity has set up the early phase trials infrastructure “Trials Acceleration Programme”. It has also conducted unique and comprehensive research into the needs of blood cancer patients, helping influencing the priorities of Bloodwise in research and patient services.
Professor Peter JohnsonPeter Johnson is Professor of Medical Oncology at the Cancer Research UK Centre in Southampton and Chief Clinician for CRUK. He trained in Medical Oncology at St Bartholomew’s Hospital in London and was Senior Lecturer in the Cancer Centre at Leeds. His research interests are in applied immunology and immunotherapy, lymphoma biology and clinical trials. He is Chief Investigator for lymphoma trials ranging from first in man novel antibody therapeutics to international randomised studies, and for the Cancer Research UK Stratified Medicine Programme.
Mr Angus McNairAngus McNair is a NIHR Academic Clinical Lecturer in General Surgery at the University of Bristol and Specialist Registrar in colorectal surgery. He trained in Bristol and the south west of England and completed his doctorate in 2011. His research interests include doctor-patient communication in cancer care, patient and public involvement in research prioritisation and randomised trial methodology.
Ms Cathy ScivierCathy Scivier has been a member of the leadership team at the Institute of Cancer Research (ICR), London for fourteen years, initially as HR Director and more recently as Chief Operating Officer, where a key part of the role was liaison with cancer research funding bodies. Cathy left the ICR in early 2016 to relocate to the north-west of England and now lives in Lancashire. For the past four years she was the ICR’s nominated Governor on the Royal Marsden NHS Foundation Trust’s Governing Body. She has an MSc in HR Management and is a Fellow of the Chartered Institute of Personnel and Development. Prior to joining the ICR she spent over 20 years in healthcare management in the NHS in south west London. She is also a trustee of the Battle Against Cancer Investment Trust Foundation, a grant giving charity.